Dutch MEB brings in shorter timetable for procedure for changing parallel package leaflet

6 January 2020

The Netherlands’ Medicines Evaluation Board (MEB) has decided to implement a shorter timetable for the procedure for changing the parallel package leaflet.

This applies to medicinal products for human use. A new version is also available of the ‘declaration accompanying a package leaflet of a parallel importation product’.

The first round of the timetable is to be shortened to 30 days. If no comment or objection has been received within 30 days, the proposed change can be implemented in the package leaflet and day 30 [month+year] must be referred to as the date under the package leaflet.
If the MEB has any comments on the proposed package leaflet, a second assessment round of 30 days will be applicable.
The package leaflet declaration for a parallel importation product has been extended to include a question about possible changes to product-specific characteristics and the extent to which the product to be imported is identical or virtually identical to the Dutch reference product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK